<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01772836</url>
  </required_header>
  <id_info>
    <org_study_id>Rempex 403</org_study_id>
    <nct_id>NCT01772836</nct_id>
  </id_info>
  <brief_title>Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination in Healthy Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RPX7009 (beta-lactamase inhibitor) is being studies in combination with a carbapenem biapenem
      to treat bacterial infections, including those due to multi-drug resistant bacteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The worldwide spread of resistance to antibiotics among Gram-negative bacteria, particularly
      members of the ESKAPE group of pathogens, has resulted in a crisis in the treatment of
      hospital acquired infections. In particular, the recent dissemination of a serine
      carbapenemase (e.g., KPC) in Enterobacteriaceae in US hospitals now poses a considerable
      threat to the carbapenems and other members of the beta-lactam class of antimicrobial agents.

      Rempex is developing a fixed combination antibiotic of a carbapenem (RPX2003 or biapenem)
      plus a new beta-lactamase inhibitor (RPX7009) which has activity against serine
      beta-lactamases, including KPC. This Phase 1 study will assess the safety, tolerability and
      pharmacokinetics and pharmacodynamics of Intravenous Biapenem and RPX7009, administered alone
      and in combination in healthy adult subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety from baseline to the end of the study</measure>
    <time_frame>Day 1 - Day 17</time_frame>
    <description>Number of patients with adverse events; assessed by patient reporting, collection of vital signs, ECGs and absolute values and changes over time of hematology, chemistry and urinalysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Pharmacokinetic (PK) parameters of RPX7009, biapenem &amp; the combination following ascending single and multiple dose administration.</measure>
    <time_frame>Day 1 - Day 14</time_frame>
    <description>Comparison will be performed between the cohorts for the plasma AUC0-t, AUC0-inf, Cmax, and Tmax.
Urine PK parameters such as amount excreted and % dose excreted will be calculated from urinary excretion data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Pharmacodynamic (PD) parameters of RPX7009, biapenem &amp; the combination following ascending single and multiple dose administration.</measure>
    <time_frame>Days 1-14</time_frame>
    <description>Serum for bactericidal titers (SBT) assessments will be collected on Days 1, 4, 7 and 14 (at the end-of-infusion (EOI)), and at 2, 4, and 8 hours after start of infusion.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single and multiple dose of normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose IV of biapenem or RPX7009</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose IV infusion of biapenem or RPX7009</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of biapenem or RPX7009</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose of biapenem or RPX7009 (for those on active drug, this will be the drug not given in the first IV treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biapenem and RPX7009 in combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose followed by a multiple dose of biapenem and RPX7009 in combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPX7009</intervention_name>
    <description>Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)</description>
    <arm_group_label>Single dose IV of biapenem or RPX7009</arm_group_label>
    <arm_group_label>Single dose of biapenem or RPX7009</arm_group_label>
    <arm_group_label>Biapenem and RPX7009 in combination</arm_group_label>
    <other_name>(beta-lactamase inhibitor)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biapenem</intervention_name>
    <description>Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)</description>
    <arm_group_label>Single dose IV of biapenem or RPX7009</arm_group_label>
    <arm_group_label>Single dose of biapenem or RPX7009</arm_group_label>
    <arm_group_label>Biapenem and RPX7009 in combination</arm_group_label>
    <other_name>RPX2003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)</description>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males and/or females, 18 to 55 years of age

          -  Body mass index (BMI) ≥ 18.5 and ≤ 29.9 (kg/m2) and weight between 55.0 and 100.0 kg
             (inclusive).

          -  Medically healthy with clinically insignificant screening results

          -  Non-tobacco/nicotine-containing product users for a minimum of 6 months prior to Day
             1.

          -  Sexually abstinent or use acceptable methods of birth control

        Exclusion Criteria:

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological,
             or psychiatric disease.

          -  History or presence of alcoholism or drug abuse within the 2 years prior to Day 1.

          -  Hypersensitivity or idiosyncratic reaction to beta-lactam antibiotics (e.g.
             penicillins, cephalosporins, carbapenems, etc.).

          -  Use of any over-the-counter (OTC) medication, including herbal products and vitamins,
             within the 7 days prior to Day 1. Up to 2 grams per day of acetaminophen is allowed
             for acute events at the discretion of the PI.

          -  Plasma donation within 7 days prior to Day 1.

          -  Subjects who have any abnormalities on laboratory values at screening or check-in (Day
             -1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jefferey Loutit, MBChB</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2013</study_first_submitted>
  <study_first_submitted_qc>January 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2013</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biapenem</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
    <mesh_term>beta-Lactamase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

